{
    "nct_id": "NCT02145026",
    "official_title": "A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Adult participants with low or intermediate-1 risk MDS\n* No previous treatment with hematopoietic growth factors within 3 months prior to screening\n* Symptomatic anemia (hemoglobin \\<10 g/dL) as determined by investigator\n* Serum erythropoietin \\<500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment\n* Require no red blood cell transfusion or dependent on \\<4 units within 8 weeks prior to screening\n* Clinically stable for at least 1 month prior to entry into the study\n* For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception\n\nExclusion Criteria:\n\n* Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment\n* Poorly controlled hypertension as assessed by the investigator\n* History of Acute Myeloid Leukemia (AML) or high risk for AML\n* Administration of another investigational drug within 1 month before screening or planned during the study period\n* Previously documented evidence of Pure Red Cell Aplasia (PRCA)\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Adult participants with low or intermediate-1 risk MDS\n* No previous treatment with hematopoietic growth factors within 3 months prior to screening\n* Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator\n* Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment\n* Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening\n* Clinically stable for at least 1 month prior to entry into the study\n* For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception",
        "exclusion": "* Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment\n* Poorly controlled hypertension as assessed by the investigator\n* History of Acute Myeloid Leukemia (AML) or high risk for AML\n* Administration of another investigational drug within 1 month before screening or planned during the study period\n* Previously documented evidence of Pure Red Cell Aplasia (PRCA)"
    }
}